Mingxing Teng

Assistant Professor

Baylor College of Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Mingxing Teng is an Assistant Professor at Baylor College of Medicine in the United States. His research focuses on innovative approaches in drug development, including work on molecular glues, PROTACs, and novel drug metabolism mechanisms. Recent publications highlight his contributions to the fields of enzyme activation and targeted therapies, reflecting a commitment to advancing pharmacological sciences.

Articles (15)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (4)

MURUGESAN PALANIAPPAN

Assistant Professor

Baylor College of Medicine

UNITED STATES

View details

Feng Li

Associate Professor

Baylor College of Medicine

UNITED STATES

View details

Eric S. Fischer

Associate Professor

Harvard Medical School

UNITED STATES

View details

Jin Wang

Professor

Baylor College of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mingxing Teng

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Template-assisted covalent modification underlies activity of covalent molecular glues

On-demand modular assembly for expedited PROTAC development

CYP3A Mediates an Unusual C(sp2)−C(sp3) Bond Cleavage via Ipso‐Addition of Oxygen in Drug Metabolism

Reversible male contraception by targeted inhibition of serine/threonine kinase 33

The rise of degrader drugs

Advancing ASMS with LC‐MS/MS for the discovery of novel PDCL2 ligands from DNA‐encoded chemical library selections

Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader

Unlocking DCAFs To Catalyze Degrader Development: An Arena for Innovative Approaches

Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections

The Pursuit of Enzyme Activation: A Snapshot of the Gold Rush

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug

Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216

Targeting transcription cycles in cancer

Exploring Ligand-Directed N-Acyl-N-alkylsulfonamide-Based Acylation Chemistry for Potential Targeted Degrader Development

Targeting oncoproteins with a positive selection assay for protein degraders

Collaborators (4)

MURUGESAN PALANIAPPAN

Feng Li

Eric S. Fischer

Jin Wang

Make your next move.